首页 > 市场调查报告书 > 製药

基因治疗学和RNAi 以基因为基之药物开发

市场调查报告书

商品编码

1419131

基因编辑市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按组件、技术、应用、最终用户和地理位置

Gene Editing Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Component, Technology, Application, End User, and Geography

出版日期: 2023年12月05日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格

简介目录

基因编辑市场规模预计将从2022年的65.42亿美元成长到2030年的239.02亿美元；预计2022-2030年CAGR为17.6%。

基因编辑市场的成长归因于癌症和其他遗传疾病的增加以及基因研究投资的增加。然而，基因组设备的高成本阻碍了市场的成长。

个人化医疗是利用患者的遗传和环境资料提供最佳医疗保健的领域。它基于每个患者都是独特的并且需要个别化药物治疗的原则。由于它是一个快速发展的领域，目前已纳入多个医疗保健系统。对基因组进行精确改变的能力为开发标靶疗法和个人化医疗开闢了新的可能性。基因编辑在个人化医疗中至关重要，它可以根据患者的遗传讯息为个别患者量身定制治疗方案。它提供了该领域的各种应用。首先，像 CRISPR-Cas9 这样的基因编辑技术可以纠正或修改与遗传性疾病相关的特定基因，从而有可能为囊性纤维化和其他遗传性疾病等疾病提供治疗或治癒方法。其次，基因编辑有助于药物基因组学，使研究人员能够研究个体的遗传变异如何影响他们的药物反应。这些知识有助于制定个人化治疗计划和优化药物剂量。

基因编辑在个人化癌症治疗中也显示出前景，可以编辑免疫细胞以更好地瞄准和摧毁癌细胞。此外，基因编辑可以透过增强免疫细胞识别和改变病原体来预防和治疗传染病。它还透过创建准确的疾病模型来促进疾病建模和药物开发，使研究人员能够更好地了解疾病并开发个人化的治疗方法。这些应用展示了基因编辑在推进个人化医疗方面的潜力，从而实现针对个别基因谱的客製化治疗。个人化医疗中的基因编辑仍在推进，需要进一步的研究和临床试验来确保安全性和有效性。

对个人化医疗日益增长的需求是推动基因编辑市场成长的主要因素之一。基因编辑技术使得基于个体基因组成的客製化疗法和治疗成为可能。 2021 年 7 月，美国 FDA 授权一名患者接受基于 CRISPR 的基因突变客製化治疗。波士顿非营利性治癒罕见疾病组织启动了这项临床试验，该试验标誌着许多里程碑，包括首次个人化 CRISPR 疗法和首次实施任何形式的基因编辑治疗肌肉营养不良症的临床试验。

透过这种个人化的医疗方法，可以提高患者的健康水平、减少不良反应并获得更好的治疗结果。对标靶治疗的需求和对个人化医疗的日益了解是基因编辑技术采用和发展的主要因素。正在开发的基因治疗候选药物数量不断增加，凸显了个人化医疗和治疗以前无法治癒的疾病方面实现变革性突破的潜力，有利于市场成长。

生产成本取决于不同参与者提供的不同应用的基因组编辑包。与基因编辑设备相关的成本可能很高。 CRISPR-Cas9 等基因编辑技术需要专门的实验室设备，包括 DNA 定序仪、热循环仪、萤光显微镜和电穿孔设备。这些仪器的价格很高，从数千美元到数百万美元不等。美国食品药物管理局 (FDA) 已批准四种基因治疗方法。 Kymriah 和 Yescarta 是两种嵌合抗原受体（CAR T 细胞）治疗方法。 Yescarta 的市场价格为 373,000 美元，而 Kymriah 的价格在 373,000 美元至 475,000 美元之间，具体取决于癌症类型。 FDA 于 2017 年批准 Luxturna 用于治疗一种罕见的遗传性失明，该疾病影响了美国 1,000 至 2,000 人。该手术的费用为每隻眼睛 425,000 美元。 Zolgensma 于 2020 年获得许可，用于治疗两岁以下儿童的一种罕见的儿童疾病，称为脊髓性肌肉萎缩症。每位患者一次静脉注射的费用为 210 万美元。生产成本随着生产过程中增加的工序而增加。

此外，基因组编辑方法的验证和评估还有额外的挑战和成本。如果验证显示负面结果，则会执行重复的程序，并在相同的程序上花费数百和数千美元。因此，在基因组编辑产生的总成本中，三分之二用于验证。因此，生产成本是限制市场成长的主要因素之一。

基于组件的见解

根据组件，基因编辑市场分为试剂和耗材、软体和系统以及服务。 2022 年，服务细分市场占据最大市场份额。然而，预计 2022 年至 2030 年，试剂和消耗品细分市场的CAGR最高。

国际癌症研究机构和世界卫生组织（WHO）是准备基因编辑市场报告时参考的主要和次要来源之一。

欧洲
- 德国
- 法国
- 义大利
- 西班牙
- 英国
- 欧洲其他地区
亚太
- 澳洲
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地区

第 12 章：产业格局

併购
协议、合作、合资企业
新产品发布
扩张和其他策略发展

第13章：竞争格局

关键参与者的热图分析
公司定位与专注

第 14 章：基因编辑市场 - 主要公司概况

Thermo Fisher Scientific Inc.

注意 - 将为以下公司列表提供类似信息

默克公司
龙沙
金斯瑞
CRISPR疗法
珀金埃尔默公司
安捷伦科技
精密生物科学
桑加莫治疗公司
新英格兰生物实验室
诺华公司

第 15 章：附录

词彙表
关于 Insight Partners
市场情报云

简介目录

Product Code: TIPRE00032626

The gene editing market size is expected to grow from US$ 6.542 billion in 2022 to US$ 23.902 billion by 2030; it is estimated to record a CAGR of 17.6% during 2022-2030.

The growth of the gene editing market is attributed to the increase in cancer and other genetic disorders and growing investment in genetic research. However, the high cost of genomic equipment hinders the market growth.

Personalized medicine is the field that utilizes patients' genetic and environmental data to deliver optimal healthcare. It is based on the principle that every patient is unique and requires individualistic pharmacological treatment. Since it is a rapidly evolving area, it is presently incorporated into several healthcare systems. The ability to make precise changes in the genome opens new possibilities for developing targeted therapies and personalized medicine. Gene editing is crucial in personalized medicine by tailoring medical treatments to individual patients based on their genetic information. It offers various applications in the field. Firstly, gene editing techniques like CRISPR-Cas9 enable the correction or modification of specific genes associated with genetic disorders, potentially providing treatments or cures for conditions such as cystic fibrosis and other genetic disorders. Secondly, gene editing aids in pharmacogenomics, allowing researchers to study how an individual's genetic variation impacts their medication response. This knowledge helps in developing personalized treatment plans and optimizing drug dosage.

Gene editing has also shown promise in personalized cancer therapy, where immune cells can be edited to better target and destroy cancer cells. Furthermore, gene editing can contribute to preventing and treating infectious diseases by enhancing immune cell recognition and modifying pathogens. It also facilitates disease modeling and drug development by creating accurate disease models, enabling researchers to understand diseases better and develop personalized treatment approaches. These applications demonstrate the potential of gene editing in advancing personalized medicine, enabling tailored treatments specific to an individual genetic profile. Gene editing in personalized medicine is still advancing, and further research and clinical trials are needed to ensure safety and efficacy.

The growing need for personalized medicine is one of the main factors propelling the growth of the gene editing market. Gene editing technology makes customized therapies and treatments based on an individual's genetic composition possible. In July 2021, the US FDA authorized one patient to receive a tailored CRISPR-based gene therapy for their mutation. The Boston non-profit Cure Rare Disease initiated the clinical trial, which marked numerous milestones, including the first-ever personalized CRISPR therapy and the first clinical trial to implement any form of gene editing for muscular dystrophy treatment.

Increased patient well-being, fewer adverse effects, and better treatment outcomes are all possible with this personalized approach to medicine. The demand for targeted therapeutics and the increasing understanding of personalized medicine have been major factors in the uptake and development of gene editing technology. The growing number of gene therapy candidates in the development pipeline highlights the potential for transformative breakthroughs in personalized medicine and treating previously incurable diseases, favoring market growth.

The cost of production is determined by the packages of genome editing for different applications offered by different players. The costs associated with gene editing equipment can be substantial. Gene editing technologies like CRISPR-Cas9 require specialized laboratory equipment, including DNA sequencers, thermal cyclers, fluorescence microscopes, and electroporation devices. These instruments have a high price tag, ranging from thousands to millions of dollars. The US Food and Drug Administration (FDA) has authorized four gene treatments. Kymriah and Yescarta are two chimeric antigen receptor (CAR T-cell) treatments. Yescarta costs US$ 373,000 in the market, whereas Kymriah costs between US$ 373,000 and US$ 475,000, depending on the kind of cancer. The FDA licensed Luxturna in 2017 to treat a rare kind of inherited blindness that affects 1,000 to 2,000 people in the US. The cost of this procedure is US$ 425,000 per eye. Zolgensma was licensed in 2020 to treat a rare childhood condition called spinal muscular atrophy in children under the age of two. Per patient, a single intravenous injection costs US$ 2.1 million. The cost of production is increased based on the procedures added during the production.

In addition, additional challenges and costs are associated with the validation and evaluation of genome editing methods. If the validation shows negative results, repetitive procedures are performed, and hundreds and thousands of dollars are spent on the same procedures. Thus, out of the total cost incurred in the production of genome editing, two-thirds is spent on validation. Hence, the cost of production is among the primary factors restraining the market's growth.

Components-Based Insights

Based on components, the gene editing market is segmented into reagents and consumables, software and systems, and services. The services segment dominated with the largest share of the market in 2022. However, the reagents and consumables segment is anticipated to register the highest CAGR from 2022 to 2030.

The International Agency for Research on Cancer and the World Health Organization (WHO) are among the primary and secondary sources referred to while preparing the gene editing market report.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Gene Editing Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Gene Editing Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Gene Editing Market - Global Market Analysis

6.1 Gene Editing - Global Market Overview
6.2 Gene Editing - Global Market and Forecast to 2030

7. Gene Editing Market - Revenue Analysis (USD Million) - By Technology, 2020-2030

7.1 Overview
7.2 Clustered Regularly Interspaced Short Palindromic Repeats
7.3 Transcription Activator-Like Effector Nucleases
7.4 Zinc Finger Nucleases
7.5 Other Technologies

8. Gene Editing Market - Revenue Analysis (USD Million) - By Component, 2020-2030

8.1 Overview
8.2 Reagents and Consumables
8.3 Software and Systems
8.4 Services

9. Gene Editing Market - Revenue Analysis (USD Million) - By Application, 2020-2030

9.1 Overview
9.2 Clinical Applications
9.3 Genetic Engineering

10. Gene Editing Market - Revenue Analysis (USD Million) - By End User, 2020-2030

10.1 Overview
10.2 Pharmaceutical Companies and Biotechnology Companies
10.3 Academics and Government Research Institutes
10.4 Clinical Research Organizations

11. Gene Editing Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

11.1 North America
- 11.1.1 North America Gene Editing Market Overview
- 11.1.2 North America Gene Editing Market Revenue and Forecasts to 2030
- 11.1.3 North America Gene Editing Market Revenue and Forecasts and Analysis - By Technology
- 11.1.4 North America Gene Editing Market Revenue and Forecasts and Analysis - By Component
- 11.1.5 North America Gene Editing Market Revenue and Forecasts and Analysis - By Application
- 11.1.6 North America Gene Editing Market Revenue and Forecasts and Analysis - By End User
- 11.1.7 North America Gene Editing Market Revenue and Forecasts and Analysis - By Countries
  - 11.1.7.1 United States Gene Editing Market
    - 11.1.7.1.1 United States Gene Editing Market, by Technology
    - 11.1.7.1.2 United States Gene Editing Market, by Component
    - 11.1.7.1.3 United States Gene Editing Market, by Application
    - 11.1.7.1.4 United States Gene Editing Market, by End User
  - 11.1.7.2 Canada Gene Editing Market
    - 11.1.7.2.1 Canada Gene Editing Market, by Technology
    - 11.1.7.2.2 Canada Gene Editing Market, by Component
    - 11.1.7.2.3 Canada Gene Editing Market, by Application
    - 11.1.7.2.4 Canada Gene Editing Market, by End User
  - 11.1.7.3 Mexico Gene Editing Market
    - 11.1.7.3.1 Mexico Gene Editing Market, by Technology
    - 11.1.7.3.2 Mexico Gene Editing Market, by Component
    - 11.1.7.3.3 Mexico Gene Editing Market, by Application
    - 11.1.7.3.4 Mexico Gene Editing Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

11.2 Europe
- 11.2.1 Germany
- 11.2.2 France
- 11.2.3 Italy
- 11.2.4 Spain
- 11.2.5 United Kingdom
- 11.2.6 Rest of Europe
11.3 Asia-Pacific
- 11.3.1 Australia
- 11.3.2 China
- 11.3.3 India
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 Rest of Asia-Pacific
11.4 Middle East and Africa
- 11.4.1 South Africa
- 11.4.2 Saudi Arabia
- 11.4.3 U.A.E
- 11.4.4 Rest of Middle East and Africa
11.5 South and Central America
- 11.5.1 Brazil
- 11.5.2 Argentina
- 11.5.3 Rest of South and Central America

12. Industry Landscape

12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration

14. Gene Editing Market - Key Company Profiles

14.1 Thermo Fisher Scientific Inc.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments

Note - Similar information would be provided for below list of companies